RESUMO
Weight loss leading to cachexia is associated with poor treatment response and reduced survival in pancreatic cancer patients. We aim to identify indicators that allow for early detection that will advance our understanding of cachexia and will support targeted anti-cachexia therapies. A total of fifty pancreatic cancer patients were analysed for skeletal muscle and visceral adipose tissue (VAT) changes using computed tomography (CT) scans. These changes were related to physical characteristics, secondary disease states and treatment parameters. Overall, patients lost 1.72 (SD 3.29) kg of muscle and 1.04 (SD 1.08) kg of VAT during the disease trajectory (413 (SD 213) d). After sorting patients into tertiles by rate of VAT and muscle loss, patients losing VAT at > -0.40 kg/100 d had poorer survival outcomes compared with patients with < -0.10 kg/100 d of VAT loss (P= 0.020). Patients presenting with diabetes at diagnosis demonstrated significantly more and accelerated VAT loss compared with non-diabetic patients. In contrast, patients who were anaemic at the first CT scan lost significantly more muscle tissue and at accelerated rates compared with non-anaemic patients. Accelerated rates of VAT loss are associated with reduced survival. Identifying associated features of cachexia, such as diabetes and anaemia, is essential for the early detection of cachexia and may facilitate the attenuation of complications associated with cachexia.
Assuntos
Anemia/complicações , Caquexia/patologia , Complicações do Diabetes/patologia , Gordura Intra-Abdominal/patologia , Músculo Esquelético/patologia , Neoplasias Pancreáticas/patologia , Neoplasias Pancreáticas/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Anemia/fisiopatologia , Composição Corporal , Caquexia/complicações , Caquexia/diagnóstico por imagem , Caquexia/etiologia , Complicações do Diabetes/fisiopatologia , Diagnóstico Precoce , Feminino , Humanos , Gordura Intra-Abdominal/diagnóstico por imagem , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/diagnóstico por imagem , Estadiamento de Neoplasias , Neoplasias Pancreáticas/complicações , Neoplasias Pancreáticas/terapia , Sarcopenia/complicações , Sarcopenia/diagnóstico por imagem , Sarcopenia/etiologia , Sarcopenia/patologia , Índice de Gravidade de Doença , Análise de Sobrevida , Tomografia Computadorizada por Raios XRESUMO
Children with malignant lymphoma undergo many diagnostic procedures that involve exposure to ionising radiation. In addition, many, but by no means all, undergo further exposure to ionising radiation during radiotherapy. While therapeutic radiation exposures are prescribed, the extent of radiation exposure arising from diagnostic procedures utilised in such children is largely unknown. We completed an audit of the radiation doses arising from diagnostic imaging procedures performed in a cohort of children with malignant lymphoma. The cumulative effective radiation dose associated with radiographic and radioisotopic procedures was derived for 81 children and adolescents with malignant lymphoma during their diagnosis, treatment and follow-up. Thirty-eight of the 42 patients (90%) with Hodgkin lymphoma were alive at study termination, with follow-up periods ranging from 1.9 to 11.7 years (median 5.3). Thirty-three of the 39 patients (85%) with non-Hodgkin lymphoma were alive at study termination with follow-up periods ranging from 2.4 to 12.3 years (median 7.5). The median effective dose was 518 mSv for patients with Hodgkin lymphoma and 309 mSv for those with non-Hodgkin lymphoma. The maximum effective dose was 1.7 Sv. The principal contributors to the effective dose were computed tomography (CT) and nuclear medicine imaging procedures using (67)Ga. Protocols for the management of children and adolescents with malignant lymphoma should be reviewed in order to reduce the radiation detriment without loss of essential diagnostic information.
Assuntos
Carga Corporal (Radioterapia) , Linfoma/diagnóstico , Linfoma/mortalidade , Doses de Radiação , Irradiação Corporal Total/estatística & dados numéricos , Adolescente , Criança , Pré-Escolar , Diagnóstico por Imagem , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Masculino , Ontário/epidemiologia , Prevalência , Medição de Risco , Fatores de Risco , Análise de Sobrevida , Taxa de Sobrevida , Adulto JovemRESUMO
The use of fluoroscopy in interventional cardiology procedures may expose patients to levels of radiation that manifest in unintended outcomes. Such outcomes may include skin injury and cancer. Currently, there is limited understanding of the magnitude of dose administered in an individual procedure. Canada does not have a formal policy for monitoring and recording the radiation dose administered to patients. This article reviews existing American, European and international policies for both monitoring administered radiation dose and patient follow-up. As a subsequent focus, this article presents the process for setting benchmarks for optimizing administered dose in the Hamilton Health Sciences Heart Investigation Unit.